On March 20, GLONGHUI (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biotech”), recently received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” on the antibody drug conjugate (ADC) SYS6023, and will conduct clinical trials in the near future.
SYS6023 is a monoclonal antibody drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis, releases toxins, and kills tumor cells. The approved clinical indication for this product is advanced solid tumors according to Class 1 of therapeutic biological products. Preclinical studies have shown that SYS6023 has shown good anti-tumor effects on various types of cancer and has high clinical development value. A number of patent applications have been submitted for this product.